Factors influencing adherence in Hepatitis-C infected patients: a systematic review

BMC Infectious Diseases

Dawid Pieper¹  Sunya-Lee Antoine¹  Tim Mathes¹ 

[1] Institute for Research in Operative Medicine, Faculty of Health - School of Medicine, Witten/Herdecke University, Ostmerheimer Str. 200, Building 38, D- 51109 Cologne, Germany

关键词: Systematic review;    Hepatitis-C;    Ribavirin;    Medication adherence;   

Others  :  1134092
DOI  :  10.1186/1471-2334-14-203

 received in 2013-12-04, accepted in 2014-04-07,  发布年份 2014

【 摘 要 】

Background

Adherence is a crucial point for the successful treatment of a hepatitis-C virus infection. Studies have shown that especially adherence to ribavirin is important.

The objective of this systematic review was to identify factors that influence adherence in hepatitis-C infected patients taking regimes that containing ribavirin.

Methods

A systematic literature search was performed in Medline and Embase in March 2014 without limits for publication date. Titles and abstracts and in case of relevance, full-texts were screened according to predefined inclusion criteria. The risk of bias was assessed. Both process steps were carried out independently by two reviewers. Relevant data on study characteristics and results were extracted in standardized tables by one reviewer and checked by a second. Data were synthesized in a narrative way using a standardized procedure.

Results

Nine relevant studies were identified. The number of analyzed patients ranged between 12 and 5706 patients. The study quality was moderate. Especially the risk of bias regarding the measurement of influencing factors was mostly unclear.

“Psychiatric disorders” (N = 5) and having to take “higher doses of ribavirin” (N = 3) showed a negative influence on adherence. In contrast, a “HIV co-infection” (N = 2) and the “hemoglobin level” (N = 2) were associated with a positive influence on adherence. Furthermore, there is the tendency that male patients are more adherent than female patients (N = 6). “Alcohol consumption” (N = 2), “education”, “employment status”, “ethnic group“,”hepatitis-C virus RNA” (N = 4), “genotype” (N = 5), “metavir activity” (N = 1) and “weight” (N = 3) showed mostly no effect on adherence. Although, some studies showed statistically significant results for “age”, “drug use” , “genotype”, “medication dose interferon“, and “treatment experience” the effect is unclear because effect directions were partly conflicting.

The other factors were heterogeneous regarding the effect direction and/or statistical significance.

Conclusion

There are some factors that seem to show an influence on adherence. However, due to the heterogeneity (e.g. patient characteristics, regimes, settings, countries) no general conclusions can be made. The results should rather be considered as indications for factors that can have an influence on adherence in hepatitis-C infected patients taking regimes that containing ribavirin.

【 授权许可】

   
2014 Mathes et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST: Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57:1333-1342.
• [2]Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, Richardson P, El-Serag HB: Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011, 140:1182-1188. e1181
• [3]Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK: Medication compliance and persistence: terminology and definitions. Value Health 2008, 11:44-47.
• [4]Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R: Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med 2011, 155:353-360.
• [5]Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, Askari F, Sullivan P, Lok AS: Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007, 13:1100-1108.
• [6]Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki J-P, Bourlière M, Gharakhanian S, Bengtsson L, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J: Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection. N Engl J Med 2009, 360:1839-1850.
• [7]Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM: Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004, 126:1015-1023.
• [8]Marcellin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Varastet M, Lang JP, Melin P, Cacoub P, CheObs Study G: Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study. Liver Int 2011, 31:516-524.
• [9]World Health Organization: Adherence to long-term therapies: evidence for action. Book Adherence to Long-Term Therapies: Evidence for Action 2003.
• [10]Bowry AD, Shrank WH, Lee JL, Stedman M, Choudhry NK: A systematic review of adherence to cardiovascular medications in resource-limited settings. J Gen Intern Med 2011, 26:1479-1491.
• [11]Jackson CA, Clatworthy J, Robinson A, Horne R: Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 2010, 105:525-539.
• [12]Verbrugghe M, Verhaeghe S, Lauwaert K, Beeckman D, Van Hecke A: Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev 2013, 39:610-621.
• [13]Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 2000, 283:2008-2012.
• [14]Hayden JA, Chou R, Hogg-Johnson S, Bombardier C: Systematic reviews of low back pain prognosis had variable methods and results: guidance for future prognosis reviews. J Clin Epidemiol 2009, 62:e781-e796.
• [15]Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Clyne W, Aronson JK, Urquhart J: A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012, 73:691-705.
• [16]World Health Organization: List of Member States by WHO Region and Mortality Stratum. Retrieved 2013.10.14. [http://www.who.int/choice/demography/mortality_strata/en/index.html webcite]
• [17]Evon DM, Esserman DA, Bonner JE, Rao T, Fried MW, Golin CE: Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence. J Viral Hepat 2013, 20:536-549.
• [18]Wroe AL: Intentional and unintentional nonadherence: a study of decision making. J Behav Med 2002, 25:355-372.
• [19]Lehane E, McCarthy G: Intentional and unintentional medication non-adherence: a comprehensive framework for clinical research and practice? A discussion paper. Int J Nurs Stud 2007, 44:1468-1477.
• [20]National Institute for Health and Clinical Excellence: The Guidelines Manual. 2009. Retrieved 16.06.2010. [http://www.nice.org.uk/media/5F2/44/The_guidelines_manual_2009_-_All_chapters.pdf webcite]
• [21]Giannelli V, Giusto M, Farcomeni A, Ponziani FR, Pompili M, Vigano R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Morelli MC, De Martin E, Miglioresi L, Di Paolo D, Fagiuoli S, Merli M: Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. Transpl Int 2012, 25:448-454.
• [22]Martin-Santos R, Diez-Quevedo C, Castellvi P, Navines R, Miquel M, Masnou H, Soler A, Ardevol M, Garcia F, Galeras JA, Planas R, Solà R: De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther 2008, 27:257-265.
• [23]Rodis JL, Kibbe P: Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterol Nurs 2010, 33:368-373.
• [24]Sola R, Galeras JA, Montoliu S, Tural C, Force L, Torra S, Montull S, Rodriguez De Castro E, Coll S, Fuster D, Barrufet P, Sirera G, Giménez MD, Clotet B, Planas R: Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. AIDS Res Hum Retrovir 2006, 22:393-400.
• [25]Sylvestre DL, Clements BJ: Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007, 19:741-747.
• [26]Tanioka D, Iwasaki Y, Araki Y, Osawa T, Ikeda H, Ando M, Kobashi H, Sakaguchi K, Shiratori Y, Yamamoto K: Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience. Liver Int 2009, 29:721-729.
• [27]Wagner G, Chan Osilla K, Garnett J, Ghosh-Dastidar B, Bhatti L, Goetz MB, Witt M: Patient characteristics associated with HCV treatment adherence, treatment completion, and sustained virologic response in HIV coinfected patients. AIDS Res Treat 2011, 2011:903480.
• [28]Grenard JL, Munjas BA, Adams JL, Suttorp M, Maglione M, McGlynn EA, Gellad WF: Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis. J Gen Intern Med 2011, 26:1175-1182.
• [29]Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, Lo Caputo S, Narciso P, Pauluzzi S, Carosi G, Nappa S, Piano P, Izzo CM, Lichtner M, Rezza G, Monforte A, Ippolito G, d'Arminio Moroni M, Wu AW, Antinori A: Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001, 28:445-449.
• [30]Atkinson MJ, Petrozzino JJ: An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. AIDS Patient Care STDs 2009, 23:903-914.
• [31]Braitstein P, Li K, Kerr T, Montaner JS, Hogg RS, Wood E: Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone. AIDS Care 2006, 18:690-693.
• [32]Gorenoi V, Schoenermark MP, Hagen A: Interventions for enhancing medication compliance/adherence with benefits in treatment outcomes (Structured abstract). Book Interventions for enhancing medication compliance/adherence with benefits in treatment outcomes (Structured abstract) 2007.
• [33]Schellingerhout JM, Heymans MW, de Vet HCW, Koes BW, Verhagen AP: Categorizing continuous variables resulted in different predictors in a prognostic model for nonspecific neck pain. J Clin Epidemiol 2009, 62:868-874.
• [34]Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Lin Gomez S, Miles S, Neugut AI: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010, 28:4120-4128.
• [35]Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R: Adherence to hepatitis C virus therapy in HIV/hepatitis C-coinfected patients. AIDS Behav 2013, 17:94-103.
• [36]Sinnott SJ, Buckley C, O'Riordan D, Bradley C, Whelton H: The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis. PLoS ONE 2013, 8:e64914.
• [37]Loh A, Leonhart R, Wills CE, Simon D, Härter M: The impact of patient participation on adherence and clinical outcome in primary care of depression. Patient Educ Couns 2007, 65:69-78.
• [38]Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G: Language bias in randomised controlled trials published in English and German. Lancet 1997, 350:326-329.
• [39]Guadagnino V, Trotta MP, Carioti J, Caroleo B, Antinori A: Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users? Dig Liver Dis 2006, 38:119-124.
• [40]Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K: Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003, 37:443-451.